Key Drivers
- Cash Generation
- Low Returns
- Intangible Heavy
AIAI Summary
RVTY is now a solid execution and cash-flow story, but with the stock already pricing in a better future, the key question is whether diagnostics growth and margin expansion can broaden enough to justify the premium—or whether tariff pressure and only incremental organic growth cap upside in the mid-110s.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •Low Returns
- •Intangible Heavy
RVTY shows solid margins, strong free cash flow, and adequate liquidity, but its low capital returns, heavy intangible asset base, and rich valuation make the stock look stretched.
Price Behavior
Key Price Behavior Insights:
- •Higher-lows trend
- •Mid-110s support
- •Near-term resistance
RVTY's last month uptrend remains intact with higher lows and support in the mid-$110s, but it still needs a clear break above the $117.9 area to extend higher, while a drop below $111.4-$112.0 would weaken the trend and raise risk of a retest of $106.44.
Slight pullback from $117.88 to $116.84 shows momentum is positive but not accelerating
Sentiment & News
Key News Insights:
- •Q2 Beat
- •Raised Outlook
- •AI Demand
Revvity beat Q2 estimates, raised its full-year outlook, and reinforced its growth story with strong diagnostics demand, improving pharma/biotech orders, and new product launches expanding its lab automation and prenatal testing footprint.
The news is positive for Revvity, signaling stronger near-term performance and broader momentum across diagnostics and workflow automation that could support the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings